Herpes simplex virus types 1 and 2 HSV1 and 2, namely varicella-zoster VZV and
cytomegalovirus CMV, are among the most common pathogens worldwide. They remain in …

Background: Herpes Simplex (HSV) viruses are widely spread, highly contagious human
pathogens. The statistics indicate that 50-90% of adults worldwide are seropositive for these …

In herpes simplex virus, the simplest path to resistance to the drug acyclovir is a mutation
that knocks out the enzyme thymidinc kinasc. Such mutants arc highly attenuated in mouse …

Herpes simplex viruses (HSV), the causative agents of recurrent orofacial and anogenital
infections, can cause significant morbidity and mortality in both immunocompetent and …

The discovery of acyclovir (ACV), a nucleoside analogue, more than 30 years ago,
represents a milestone in the management of HSV and VZV infections. The modest activity …

Nucleoside analogues such as acyclovir and ganciclovir have been the mainstay of therapy
for alphaherpesviruses (herpes simplex virus (HSV) and varicella-zoster virus (VZV)) and …

In the past 4 years, interest in drug-resistant herpesviruses has evolved from the realm of
academic laboratory studies to that of great clinical importance. Recurrent and persistent …

Background Herpesviruses notably establish lifelong infections, with latency and
reactivation. Many of the known human herpesviruses infect large proportions of the …

The initial development of antiviral compounds was slow, with the first clinical antiviral agent
not available until the 1960s. Early development was hindered by the lack of understanding …

REPORTS of the clinical efficacy of acyclovir, a selective and specific inhibitor of herpesvirus
replication, appeared in the literature a decade ago. Acyclovir has become the most widely …